Tanya Dorff, MD, discusses the current treatment modalities for prostate cancer and the hope that chimeric antigen receptor T cells will improve outcomes.
Tanya Dorff, MD, a medical oncologist, section chief of Genitourinary Disease Program, and associate professor in the Department of Medical Oncology & Therapeutics Research at City of Hope, discusses the current treatment modalities for prostate cancer and the hope that chimeric antigen receptor (CAR) T cells will improve outcomes.
During the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium, Dorff presented data around the use of engineered CAR T cells in patients with metastatic castration resistant prostate cancer. Considering that CAR T-cell therapy is a novel modality in prostate cancer, Dorff explains that achieving deep remissions with standard therapy and immunotherapy has not been successful in prostate cancer.
Moreover, there Dorff believe that T-cell technology may be a solution to the problem.
0:07 | Whereas immune checkpoint inhibitors have really changed prognosis in a major way for diseases like melanoma and renal cell, creating these durable remissions, you just don't see that same impact of standard immunotherapy like checkpoint inhibitors in prostate cancer.
0:25 | So, we have a lot of great treatments for prostate cancer, many different hormonal agents that are extremely powerful and are definitely improving our patients lives and then we have chemotherapy, radioactive particles. And there is immunotherapy with sipuleucel-t, but there's nothing yet that creates really durable remissions. And so, the hope is that T-cell technology is where we might start to achieve that.